MXPA05003302A - Compuestos de piperazina terapeuticos. - Google Patents
Compuestos de piperazina terapeuticos.Info
- Publication number
- MXPA05003302A MXPA05003302A MXPA05003302A MXPA05003302A MXPA05003302A MX PA05003302 A MXPA05003302 A MX PA05003302A MX PA05003302 A MXPA05003302 A MX PA05003302A MX PA05003302 A MXPA05003302 A MX PA05003302A MX PA05003302 A MXPA05003302 A MX PA05003302A
- Authority
- MX
- Mexico
- Prior art keywords
- piperazine compounds
- therapeutic
- hydroxyiminopiperazine compound
- animal
- disclosed
- Prior art date
Links
- 150000004885 piperazines Chemical class 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- -1 Hydroxyiminopiperazine Compound Chemical class 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Otolaryngology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Nutrition Science (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41284702P | 2002-09-24 | 2002-09-24 | |
| PCT/US2003/030185 WO2004029031A2 (en) | 2002-09-24 | 2003-09-24 | Therapeutic piperazine compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05003302A true MXPA05003302A (es) | 2005-10-18 |
Family
ID=32043195
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05003302A MXPA05003302A (es) | 2002-09-24 | 2003-09-24 | Compuestos de piperazina terapeuticos. |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US7157462B2 (https=) |
| EP (2) | EP1810970B8 (https=) |
| JP (1) | JP4560610B2 (https=) |
| KR (1) | KR20050052514A (https=) |
| CN (1) | CN100393713C (https=) |
| AT (2) | ATE467627T1 (https=) |
| AU (1) | AU2003272685A1 (https=) |
| BR (1) | BR0314699A (https=) |
| CA (1) | CA2500113C (https=) |
| CY (1) | CY1106634T1 (https=) |
| DE (2) | DE60332562D1 (https=) |
| DK (1) | DK1562936T3 (https=) |
| ES (1) | ES2285170T3 (https=) |
| MX (1) | MXPA05003302A (https=) |
| NZ (1) | NZ539205A (https=) |
| PT (1) | PT1562936E (https=) |
| SI (1) | SI1562936T1 (https=) |
| WO (1) | WO2004029031A2 (https=) |
| ZA (1) | ZA200502326B (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002060446A1 (fr) | 2001-01-29 | 2002-08-08 | Shionogi & Co., Ltd. | Preparation medicamenteuse contenant du 5-methyle-1-phenyle-2-(1h)-pyridone en tant que principe actif |
| US7157462B2 (en) * | 2002-09-24 | 2007-01-02 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
| US7582635B2 (en) | 2002-12-24 | 2009-09-01 | Purdue Pharma, L.P. | Therapeutic agents useful for treating pain |
| GEP20094676B (en) * | 2003-07-24 | 2009-05-10 | Euro Celtique Sa | Piperidine compounds and pharmaceutical compositions containing them |
| DE602004017316D1 (de) | 2003-07-24 | 2008-12-04 | Euro Celtique Sa | Heteroaryl-tetrahydropyridylverbindungen, die sich für die behandlung bzw. die prävention von schmerzen eignen |
| WO2005012287A1 (en) * | 2003-08-01 | 2005-02-10 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| US8450351B2 (en) | 2005-12-20 | 2013-05-28 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| WO2007095050A2 (en) * | 2006-02-09 | 2007-08-23 | Incyte Corporation | N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase |
| CA2649881A1 (en) * | 2006-04-19 | 2007-11-01 | Jill P. Smith | Treatment of inflammatory and ulcerative diseases of the bowel with opioid antagonists |
| US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
| WO2008036642A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| US20080153845A1 (en) * | 2006-10-27 | 2008-06-26 | Redpoint Bio Corporation | Trpv1 antagonists and uses thereof |
| CA2685266C (en) * | 2007-04-27 | 2014-01-28 | Purdue Pharma L.P. | Trpv1 antagonists and uses thereof for the treatment of prevention of pain, ui and ulcer, ibd, or ibs in an animal |
| WO2009052377A1 (en) * | 2007-10-18 | 2009-04-23 | Harry Fisch | Treatment of migraine headaches using antiestrogens |
| WO2009096701A2 (en) | 2008-01-28 | 2009-08-06 | Amorepacific Corporation | Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same |
| JP5438103B2 (ja) | 2008-07-02 | 2014-03-12 | アモーレパシフィック コーポレイション | バニロイド受容体アンタゴニストとしての新規化合物、その異性体またはその薬学的に許容される塩、並びにそれを含む医薬組成物 |
| JP5465720B2 (ja) | 2008-07-08 | 2014-04-09 | インサイト・コーポレイション | インドールアミン２，３−ジオキシゲナーゼの阻害剤としての１，２，５−オキサジアゾール |
| WO2011103091A1 (en) | 2010-02-18 | 2011-08-25 | Transtech Pharma, Inc. | Phenyl-heteroaryl derivatives and methods of use thereof |
| US8921373B2 (en) | 2010-06-22 | 2014-12-30 | Shionogi & Co., Ltd. | Compounds having TRPV1 antagonistic activity and uses thereof |
| JP6130827B2 (ja) | 2011-05-17 | 2017-05-17 | 塩野義製薬株式会社 | ヘテロ環化合物 |
| PE20141531A1 (es) | 2011-06-22 | 2014-10-23 | Purdue Pharma Lp | Antagonistas de trpv1 que incluyen sustituyentes dihidroxi y sus usos |
| ES2799582T3 (es) | 2013-11-08 | 2020-12-18 | Incyte Holdings Corp | Proceso para la síntesis de un inhibidor de indoleamina 2,3-dioxigenasa |
| CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
| UA124972C2 (uk) | 2016-07-29 | 2021-12-22 | Янссен Фармацевтика Нв | Способи лікування раку передміхурової залози |
| EP3586309B1 (en) | 2017-02-24 | 2023-04-05 | Brainlab AG | Deep inspiration breath-hold setup using x-ray imaging |
| AU2022267044A1 (en) | 2021-04-26 | 2023-11-30 | Pathios Therapeutics Limited | Compounds |
| DE102022104759A1 (de) | 2022-02-28 | 2023-08-31 | SCi Kontor GmbH | Co-Kristall-Screening Verfahren, insbesondere zur Herstellung von Co-Kristallen |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4439606A (en) | 1982-05-06 | 1984-03-27 | American Cyanamid Company | Antiatherosclerotic 1-piperazinecarbonyl compounds |
| US4450272A (en) | 1982-05-06 | 1984-05-22 | American Cyanamid Company | Antiatherosclerotic 1-piperazine-thicarboxamides |
| US5316759A (en) | 1986-03-17 | 1994-05-31 | Robert J. Schaap | Agonist-antagonist combination to reduce the use of nicotine and other drugs |
| DE3822792C2 (de) | 1987-07-11 | 1997-11-27 | Sandoz Ag | Neue Verwendung von 5HT¶3¶-Antagonisten |
| US5198459A (en) | 1987-07-11 | 1993-03-30 | Sandoz Ltd. | Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents |
| US5075341A (en) | 1989-12-01 | 1991-12-24 | The Mclean Hospital Corporation | Treatment for cocaine abuse |
| US6204284B1 (en) | 1991-12-20 | 2001-03-20 | American Cyanamid Company | Use of 1-(substitutedphenyl)-3-azabicyclo[3.1.0]hexanes for the treatment of chemical dependencies |
| US5232934A (en) | 1992-07-17 | 1993-08-03 | Warner-Lambert Co. | Method for the treatment of psychomotor stimulant addiction |
| DE4234295A1 (de) | 1992-10-12 | 1994-04-14 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| US5321012A (en) | 1993-01-28 | 1994-06-14 | Virginia Commonwealth University Medical College | Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance |
| GB9306578D0 (en) | 1993-03-30 | 1993-05-26 | Merck Sharp & Dohme | Therapeutic agents |
| GB9308725D0 (en) | 1993-04-27 | 1993-06-09 | Wyeth John & Brother Ltd | Piperazine derivatives |
| US5461047A (en) | 1993-06-16 | 1995-10-24 | G. D. Searle & Co. | 2-,3-,4-,5-,6-,7-,8-,9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use |
| US5464788A (en) | 1994-03-24 | 1995-11-07 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
| FR2722788B1 (fr) | 1994-07-20 | 1996-10-04 | Pf Medicament | Nouvelles piperazides derivees d'aryl piperazine, leurs procedes de preparation, leur utilisation a titre de medicament et les compositions pharmaceutiques les comprenant |
| US5556837A (en) | 1994-08-01 | 1996-09-17 | Regeneron Pharmaceuticals Inc. | Methods for treating addictive disorders |
| US5762925A (en) | 1994-11-03 | 1998-06-09 | Sagen; Jacqueline | Preventing opiate tolerance by cellular implantation |
| CN1128139C (zh) | 1995-01-11 | 2003-11-19 | 三进制药株式会社 | 新哌嗪衍生物及其制造方法 |
| SK27598A3 (en) | 1996-06-29 | 1998-11-04 | Samjin Pharm Co Ltd | Piperazine derivatives and process for the preparation thereof |
| EP1019367A1 (en) | 1997-08-05 | 2000-07-19 | Novo Nordisk A/S | Derivatives of 2,5- and 3,5-disubstituted anilines, their preparation and use |
| EP1067123B1 (en) | 1998-03-31 | 2011-01-19 | Kyowa Hakko Kirin Co., Ltd. | Nitrogenous heterocyclic compounds |
| US6329395B1 (en) | 1998-06-08 | 2001-12-11 | Schering Corporation | Neuropeptide Y5 receptor antagonists |
| CN1129581C (zh) | 1998-09-22 | 2003-12-03 | 山之内制药株式会社 | 氰基苯基衍生物 |
| EP1424072A1 (en) | 1999-03-03 | 2004-06-02 | Samjin Pharmaceutical Co., Ltd. | N'-(pyridin-3-yl)-(4-phenylpiperazin-1-yl)-carboxyimidamide and -iminothiolate derivatives for the treatment of tumors |
| US6109269A (en) | 1999-04-30 | 2000-08-29 | Medtronic, Inc. | Method of treating addiction by brain infusion |
| AU2001280599A1 (en) | 2000-07-15 | 2002-01-30 | Smith Kline Beecham Corporation | Compounds and methods |
| EP1301484A2 (en) * | 2000-07-20 | 2003-04-16 | Neurogen Corporation | Capsaicin receptor ligands |
| CA2417507A1 (en) | 2000-08-21 | 2002-02-28 | Pacific Corporation | Novel thiourea derivatives and the pharmaceutical compositions containing the same |
| ATE328868T1 (de) | 2000-08-21 | 2006-06-15 | Pacific Corp | Neue (thio)harnstoffverbindungen und arzneimittelkompositionen, die diese enthalten |
| MY138086A (en) | 2001-09-13 | 2009-04-30 | Smithkline Beecham Plc | Novel urea derivative as vanilloid receptor-1 antagonist |
| HUP0500200A2 (hu) | 2002-01-17 | 2005-07-28 | Neurogen Corporation | Szubsztituált kinazolin-4-ilamin analógok, mint kapszaicin modulátorok és ezeket tartalmazó gyógyszerkészítmények |
| AU2003245773A1 (en) | 2002-02-15 | 2003-09-04 | Glaxo Group Limited | Vanilloid receptor modulators |
| US7074805B2 (en) | 2002-02-20 | 2006-07-11 | Abbott Laboratories | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| US20030158188A1 (en) | 2002-02-20 | 2003-08-21 | Chih-Hung Lee | Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor |
| EA200500114A1 (ru) * | 2002-06-28 | 2005-06-30 | Еуро-Селтик, С. А. | Терапевтические агенты, используемые для лечения боли |
| US7157462B2 (en) * | 2002-09-24 | 2007-01-02 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
| DE602004017316D1 (de) * | 2003-07-24 | 2008-12-04 | Euro Celtique Sa | Heteroaryl-tetrahydropyridylverbindungen, die sich für die behandlung bzw. die prävention von schmerzen eignen |
| GEP20094676B (en) * | 2003-07-24 | 2009-05-10 | Euro Celtique Sa | Piperidine compounds and pharmaceutical compositions containing them |
| PL1727801T3 (pl) * | 2003-12-30 | 2009-08-31 | Euro Celtique Sa | Piperazyny użyteczne do leczenia bólu |
-
2003
- 2003-09-23 US US10/669,823 patent/US7157462B2/en not_active Expired - Lifetime
- 2003-09-24 KR KR1020057005096A patent/KR20050052514A/ko not_active Ceased
- 2003-09-24 DE DE60332562T patent/DE60332562D1/de not_active Expired - Lifetime
- 2003-09-24 CA CA2500113A patent/CA2500113C/en not_active Expired - Fee Related
- 2003-09-24 BR BR0314699-5A patent/BR0314699A/pt not_active IP Right Cessation
- 2003-09-24 ES ES03754883T patent/ES2285170T3/es not_active Expired - Lifetime
- 2003-09-24 CN CNB03825297XA patent/CN100393713C/zh not_active Expired - Fee Related
- 2003-09-24 EP EP07104074A patent/EP1810970B8/en not_active Expired - Lifetime
- 2003-09-24 AT AT07104074T patent/ATE467627T1/de not_active IP Right Cessation
- 2003-09-24 PT PT03754883T patent/PT1562936E/pt unknown
- 2003-09-24 EP EP03754883A patent/EP1562936B1/en not_active Expired - Lifetime
- 2003-09-24 JP JP2004539882A patent/JP4560610B2/ja not_active Expired - Fee Related
- 2003-09-24 WO PCT/US2003/030185 patent/WO2004029031A2/en not_active Ceased
- 2003-09-24 DE DE60312544T patent/DE60312544T2/de not_active Expired - Lifetime
- 2003-09-24 NZ NZ539205A patent/NZ539205A/en not_active IP Right Cessation
- 2003-09-24 AU AU2003272685A patent/AU2003272685A1/en not_active Abandoned
- 2003-09-24 MX MXPA05003302A patent/MXPA05003302A/es active IP Right Grant
- 2003-09-24 SI SI200330815T patent/SI1562936T1/sl unknown
- 2003-09-24 AT AT03754883T patent/ATE356817T1/de active
- 2003-09-24 DK DK03754883T patent/DK1562936T3/da active
-
2005
- 2005-03-18 ZA ZA200502326A patent/ZA200502326B/en unknown
-
2006
- 2006-11-16 US US11/601,792 patent/US7737148B2/en not_active Expired - Lifetime
-
2007
- 2007-06-04 CY CY20071100730T patent/CY1106634T1/el unknown
-
2008
- 2008-09-29 US US12/240,688 patent/US7855210B2/en not_active Expired - Lifetime
-
2010
- 2010-11-10 US US12/943,739 patent/US20110082152A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA05003302A (es) | Compuestos de piperazina terapeuticos. | |
| ES2295609T3 (es) | Derivados de tiadiazolilpiperazina utiles para tratar o prevenir un dolor. | |
| CY1109242T1 (el) | Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου | |
| MXPA05013587A (es) | Agentes terapeuticos utiles para el tratamiento del dolor. | |
| WO2005056524A3 (en) | Therapeutic agents useful for treating pain | |
| RU94044436A (ru) | Способы подавления атрофии кожи и влагалища | |
| CY1109037T1 (el) | Πιπεραζινες χρησιμες για θεραπεια πονου | |
| AU3850600A (en) | Dalda analogs and their use | |
| SI2017276T1 (sl) | Fenil-karboksamidne spojine, uporabne za tretiranje bolečine | |
| RU94044454A (ru) | Ингибитор аутоимунных заболеваний | |
| GB0130677D0 (en) | Medicaments and novel compounds | |
| SE9802208D0 (sv) | Novel compounds | |
| GB2352972A (en) | Use of dexmedetomidine for icu sedation | |
| GEP20043227B (en) | 5HT1 Antagonists for Antidepressant Therapy | |
| SE9802209D0 (sv) | Novel compounds | |
| BG103512A (en) | Substituted pyramidine compounds and their application | |
| GEP20043231B (en) | Resorcinol Composition | |
| AU2002211217A1 (en) | Method of treating stroke | |
| MY133957A (en) | "compounds useful for the treatment or prevention of a disease mediated by the alpha-2b-adrenoceptor" | |
| MXPA05003633A (es) | 2"-oxo-voruscharina y derivados de la misma. | |
| MX9701528A (es) | Derivados de 1, 1, 2,- trifenilbut-1-eno para tratar la enfermedad de alzheimer. | |
| ES2173044A1 (es) | Glicina, n-(n-l- -glutamil-3-(nitrosotio)-l-valil) y sus aplicaciones. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |